{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE312nnn/GSE312099/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Genomics"],"species":["Homo sapiens"],"gds_type":["Genome binding/occupancy profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312099"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Immune cell sequencing after allogeneic hematopoietic cell transplantation [snATAC-seq]","description":"Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative therapy for hematologic malignancies. The primary non-relapse complication after allo-HSCT is graft-versus-host disease (GVHD). The use of T regulatory (Treg) cells to prevent GVHD has emerged as a promising allogeneic T cell immunotherapy in the form of Orca-T. However, the precise differences in immune states which may influence clinical outcomes after Orca-T compared with unmanipulated peripheral blood stem cell (PBSC) grafts remain unexplored. Using peripheral blood specimens longitudinally collected between 3 weeks and one year after leukemia treatment, we examined single-nucleus ATAC-seq and whole transcriptome sequencing (scRNA-seq) analysis of PBMC from 4 patients receiving either Orca-T or unmanipulated PBSC grafts and 2 mobilized donors.","dates":{"publication":"2026/05/27"},"accession":"GSE312099","cross_references":{"GSM":["GSM9337724","GSM9337723"],"GPL":["24676"],"GSE":["312099"],"taxon":["Homo sapiens"],"PMID":["[41758930]"]}}